Search hospitals > Michigan > Detroit
Barbara Ann Karmanos Cancer Institute
Claim this profileDetroit, Michigan 48201
Global Leader in Cancer
Global Leader in Lung Cancer
Conducts research for Breast Cancer
Conducts research for Pancreatic Cancer
Conducts research for Solid Tumors
1496 reported clinical trials
101 medical researchers
Summary
Barbara Ann Karmanos Cancer Institute is a medical facility located in Detroit, Michigan. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Pancreatic Cancer, Solid Tumors and other specialties. Barbara Ann Karmanos Cancer Institute is involved with conducting 1,496 clinical trials across 904 conditions. There are 101 research doctors associated with this hospital, such as Ammar Sukari, Anthony F. Shields, Hirva Mamdani, MD, and Dipenkumar Modi, M.D..Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
Top PIs
Ammar SukariWayne State University/Karmanos Cancer Institute3 years of reported clinical research
Expert in Squamous Cell Carcinoma
Studies Head and Neck Cancers
29 reported clinical trials
45 drugs studied
Anthony F. ShieldsBarbara Ann Karmanos Cancer Institute6 years of reported clinical research
Studies Pancreatic Cancer
Studies Solid Tumors
22 reported clinical trials
65 drugs studied
Hirva Mamdani, MDKarmanos Cancer Institute5 years of reported clinical research
Expert in Lung Cancer
Studies Non-Small Cell Lung Cancer
20 reported clinical trials
29 drugs studied
Dipenkumar Modi, M.D.Karmanos Cancer Institute3 years of reported clinical research
Studies Lymphoma
Studies Diffuse Large B-Cell Lymphoma
22 reported clinical trials
48 drugs studied
Clinical Trials running at Barbara Ann Karmanos Cancer Institute
Lung Cancer
Breast Cancer
Ovarian Cancer
Pancreatic Cancer
Esophageal cancer
Breast cancer
Cancer
Solid Tumors
Multiple Myeloma
Bladder Cancer
Neladalkib
for Non-Small Cell Lung Cancer
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC).
Recruiting2 awards Phase 34 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Proton Craniospinal Radiation
for Cancer in the Brain and Spinal Cord
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal fluid filled space that surrounds the brain and spinal cord (leptomeningeal metastasis). Patients with leptomeningeal metastasis (LM) may develop multiple areas of nervous system (neurologic) impairment that can be life-threatening. Radiation therapy (RT) effectively relieves local symptoms due to LM. RT uses high energy radiography (x-rays), particles, or radioactive seeds to kill cancer cells and shrink tumors. IFRT is commonly used to treat symptoms of LM. IFRT is radiation treatment that uses x-rays to treat specific areas of LM and to relieve and/or prevent symptoms. pCSI uses protons that can be directed with more accuracy than x-rays which allows treatment of the entire central nervous system space containing the cerebrospinal fluid (CSF), brain, and spinal cord. The pCSI treatment could delay the worsening of LM. Giving pCSI may be better than IFRT in treating LM in patients with breast or non-small cell lung cancer.
Recruiting2 awards Phase 33 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Barbara Ann Karmanos Cancer Institute?
Barbara Ann Karmanos Cancer Institute is a medical facility located in Detroit, Michigan. This center is recognized for care of Cancer, Lung Cancer, Breast Cancer, Pancreatic Cancer, Solid Tumors and other specialties. Barbara Ann Karmanos Cancer Institute is involved with conducting 1,496 clinical trials across 904 conditions. There are 101 research doctors associated with this hospital, such as Ammar Sukari, Anthony F. Shields, Hirva Mamdani, MD, and Dipenkumar Modi, M.D..
Where is Barbara Ann Karmanos Cancer Institute located?
The Barbara Ann Karmanos Cancer Institute, situated in midtown Detroit, MI at 4100 John R St, is the sole National Cancer Institute (NCI)-designated comprehensive cancer center in southeast Michigan. It stands among only 54 centers of its kind across the United States.
Who should I call to ask about financial aid or insurance network?
**Financial Assistance and Insurance Inquiries at Barbara Ann Karmanos Cancer Institute:**
- For financial assistance, contact McLaren Patient Financial Services at (844) 321-1557 or submit the Financial Assistance Application to: McLaren Corporate Services, Attn: Revenue Cycle Operations, 50820 Schoenherr Rd., Shelby Township, MI 48315.
- For insurance-related questions, call the hospital's general information line at 1-800-KARMANOS (1-800-527-6266).
What insurance does Barbara Ann Karmanos Cancer Institute accept?
The Barbara Ann Karmanos Cancer Institute accepts most health insurance plans, including Aetna, Blue Cross Blue Shield of MI, Cigna, Humana, Molina, and United Health Care among others. It is crucial to verify with your insurance provider about coverage for procedures at the Karmanos Cancer Institute before scheduling your first appointment. Patients are encouraged to review their insurance coverage annually to avoid unexpected bills.
What awards or recognition has Barbara Ann Karmanos Cancer Institute received?
The Barbara Ann Karmanos Cancer Institute, located in Detroit, Michigan, was awarded a $352,437 grant by the U CAN-CER VIVE Foundation in 2022 to support its research efforts. It has been recognized as a National Cancer Institute (NCI)-designated comprehensive cancer center since 1978, a testament to its scientific excellence and integrated research approaches in the fight against cancer.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.